


## Data Sheet

Product Name:	IRAK inhibitor 3
Cat. No.:	CS-0605
CAS No.:	1012343-93-9
Molecular Formula:	C <sub>21</sub> H <sub>21</sub> N <sub>5</sub> O <sub>4</sub> S
Molecular Weight:	439.49
Target:	IRAK
Pathway:	Immunology/Inflammation; Protein Tyrosine Kinase/RTK
Solubility:	DMSO : 13 mg/mL (29.58 mM; Need ultrasonic and warming)



### BIOLOGICAL ACTIVITY:

IRAK inhibitor 3 is an interleukin-1 (IL-1) receptor-associated kinase (**IRAK**) kinase modulator extracted from patent WO2008030579 A2. IC<sub>50</sub> & Target: IRAK<sup>[1]</sup> **In Vitro:** IRAK inhibitor 3 is an IRAK modulator, which can be used for treating an inflammatory condition, cell proliferative disorder, immune disorder<sup>[1]</sup>.

### PROTOCOL (Extracted from published papers and Only for reference)

**Kinase Assay:** <sup>[1]</sup> 5 µL of a solution of IRAK inhibitor 3 at a concentration of 50 µM or less in 1% (v/v) DMSO is added to the wells of a 96-well area Black Polystyrene plates. The final concentrations in the reaction well are 10 µM ATP, 0.5 µM IRAK4 CH373, 1.6 µM IRAK1 peptide, 1 mM MgCl<sub>2</sub>, 2 mM DTT, 5 mM MnCl<sub>2</sub>, 0.01 % BSA, and 0.01 % Tween-20. The volume of the reaction is 45 µL. The reaction mixture is incubated at room temperature for 30 minutes and stopped with the addition of 5 µL of 100 mM EDTA<sup>[1]</sup>.

### References:

[1]. Thomas Durand-Reville, et al. Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder. WO 2008030579 A2.

### CAIndexNames:

Benzenesulfonamide, 4-[[[3-(3,4-dimethoxyphenyl)imidazo[1,2-b]pyridazin-6-yl]amino]methyl]-

### SMILES:

O=S(C1=CC=C(CNC2=NN3C(C4=CC(OC)=C(C=C4)OC)=CN=C3C=C2)C=C1)(N)=O

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 732-484-9848

Fax: 888-484-5008

E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA